Overview of vitiligo research October - December 2015

Highlights

  • Blocking JAK1/2 activity with ruxolitinib might be a strategy in vitiligo treatment but future studies are required to confirm efficiency and safety.
  • Mechanisms underlying improved efficiency of NB-UVB phototherapy for vitiligo when combined with topical tacrolimus are described.
  • Once-a-week treatment with targeted UVB seems to as efficient as conventionally accepted twice weekly schedule (in terms of administered UVB dosage and number of sessions) in inducing repigmentation of vitiligo lesions.
  • Additional excimer laser phototherapy combined with NB-UVB for lesions with slow response or no further improvement with NB-UVB treatment might improve overall regimentation.

This is a review of research results in the vitiligo field which were indexed in the PubMed database (www.ncbi.nlm.nih.gov/pubmed) for the period from October 2015 till December 2015. Abstracts of papers were retrieved from the PubMed database using the search term “vitiligo” with a filter set up to retrieve records with creation date between October 01, 2015 and December 31, 2015. Retrieved records were manually checked for a relevance to and significance for the field of vitiligo research. Fifty nine records were found to be relevant and of interest, and were included in this quarterly overview.

Contents

  • Reviews & Comments 
  • Disease Management And Clinical Features 
  • Epidemiology 
  • Comorbidities 
  • Quality of life (QoL) 
  • Vitiligo triggers 
  • Case reports 
  • Understanding mechanisms of vitiligo pathogenesis 
  • Genetic studies 
  • Candidate biomarkers 
  • Mechanisms of treatments 
  • Methodological advancements 
  • Novel treatment modalities 
  • Clinical studies and trials

Download full report (pdf)

image description

I support the petition to designate June 25 as Vitiligo World Day and save millions of people worldwide from social isolation and persecution.

All

Famous vitiligans

FAQ

All FAQs

To download this free file, please tell us a little bit about yourself.

Close